ArticleScience advances2023
BRAF
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Impact of non-genetic heterogeneity of BRAF-mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics.International journal of cancer · 2026Article
- NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.Journal of the National Cancer Institute · 2026Article
- Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications.Molecular cancer · 2026Review
- Kinase signaling cascades: an updated mechanistic landscape.Chemical science · 2025Review
- Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies.ESMO gastrointestinal oncology · 2025Review
- Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold.Theranostics · 2025Article
- The mTOR pathway controls phosphorylation of BRAF at T401.Cell communication and signaling : CCS · 2024Article
- Clinical phenotype of adult-onset systemic histiocytosis harboringHaematologica · 2024Article
- Improving gastrointestinal cancer therapy by uniting stakeholders.ESMO gastrointestinal oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 3 countries.
Manuel LauingerInstitute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0001-5359-527X
Daniel ChristenInstitute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
Rhena F U KlarInstitute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0003-3264-8170
Carole RoubatyDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.ORCID 0000-0003-1658-8972
Christoph E HeiligDivision of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0001-8869-1421
Michael StumpeDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.ORCID 0000-0002-9443-9326
Jennifer J KnoxPanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Nikolina RadulovichPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-8224-7263
Laura TamblynPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Irene Y XiePrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-4911-1364
Peter HorakDivision of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0003-4536-9306
Andrea ForschnerDepartment of Dermatology, University Hospital of Tübingen, Tübingen, Germany.ORCID 0000-0002-6185-4945
Michael BitzerGerman Cancer Consortium (DKTK), DKFZ partner site Tübingen, Eberhard Karls University, Tübingen, Germany.ORCID 0000-0002-4463-8263
Uwe A WittelDepartment of General and Visceral Surgery, University of Freiburg Medical Center, Faculty of Medicine, 79106 Freiburg, Germany.ORCID 0000-0001-6194-2374
Melanie BoerriesGerman Cancer Consortium (DKTK), partner site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-3670-0602
Claudia R BallDepartment for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.ORCID 0000-0002-1749-3791
Christoph HeiningDepartment for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.ORCID 0000-0002-1256-8387
Hanno GlimmDepartment for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.ORCID 0000-0003-4104-1135
Martina FröhlichComputational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Daniel HübschmannGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-6041-7049
Steven GallingerPanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Ralph FritschDepartment of Internal Medicine I (Hematology, Oncology, and Stem Cell Transplantation), University Hospital of Freiburg, Freiburg, Germany.
Stefan FröhlingDivision of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0001-7907-4595
Grainne M O'KanePanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.ORCID 0000-0002-8690-403X
Jörn DengjelDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.ORCID 0000-0002-9453-4614
Tilman BrummerInstitute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0003-4387-7905
German Cancer Research Center · DEUniversity of Freiburg · DEOntario Institute for Cancer Research · CAUniversity Health Network · CAUniversity of Fribourg · CHUniversity Medical Center Freiburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
In-frame
Indexed as
HSP90 Heat-Shock ProteinsProto-Oncogene Proteins B-rafAmino AcidsAminopyridinesDimerizationHumansAmino AcidsAminopyridinesBRAF protein, humanHSP90 Heat-Shock ProteinsnaporafenibProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.